• McKinsey & Company notes that portfolio model is growing in popularity amongst companies and investors
• HLTT recently acquired precision oncology company Varian Biopharma
• Report shows that more than $5.5 billion in capital has been raised in past six years by companies with biotech portfolio models

An emerging trend in biotechnology involves abandoning a single shot on goal approach in favor of a broader strategy with different portfolio companies under one umbrella. The old incubator approach with a new flare, the trend involves a portfolio manager utilizing a variety of skillsets to assemble a group of subsidiaries, each committed to a different specialty or drug program. It can be a de-risking methodology that simultaneously amplifies the upside of the parent company, and biotech players like Healthtech Solutions (OTC: HLTT) have pivoted to this model, primarily through its recent acquisition of Varian Biopharmaceuticals (https://ibn.fm/ZLSAj). With the buyout of Varian Biopharma, Healthtech expanded its portfolio to three distinct healthcare subsidiaries. MediScan, Inc. has developed disruptive technology that converts 2D images from a portable ultrasound machine into 3D, high-definition images, a leap forward in imaging to improve diagnoses by providing point-of-care imaging on par with X-rays, MRIs and CT scans. The company’s RevHeart unit is advancing critical research into the treatment of COVID-related heart muscle injury. As noted in a recent report by McKinsey & Company, the model is growing in popularity amongst companies and investors. Firms like BridgeBio Pharma (NASDAQ: BBIO) and Biohaven Pharmaceutical (NYSE: BHVN) are two blue chips operating under the central-management-with-multiple-subsidiaries structure, demonstrating the strong investor interest. All told, the report shows that more than $5.5 billion in capital has been raised in the past six years by companies with biotech portfolio models (https://ibn.fm/AUNNS). Varian Biopharma, which will be housed as a new Healthtech Oncology, Inc. subsidiary, is a precision oncology company specializing in the development of atypical protein kinase C iota, or aPKCi, inhibitors for different tumor types. Varian Bio’s two lead candidates are still being prepared for clinical trials. VAR-101 is a topical formulation for basal cell carcinoma, the most common type of skin cancer, affecting about 4.3 million Americans each year (https://ibn.fm/jK1ta). VAR-102 is an experimental oral drug that will be tested against a battery of resilient tumors where research has shown aPCKi inhibition could be an effective pathway, including pancreatic, colorectal and non-small cell lung cancers (“NSCLC”). A new approach in precision oncology, aPKCi inhibition innovates through regulation of transcription factors such as GLI-1 and K-RAS—proteins known to be integral in cancer pathogenesis. Varian appears to be on the leading edge, as K-RAS G12C is considered the most prevalent emerging biomarker in NSCLC (https://ibn.fm/7Brip). Investors from small retail to institutions seem to value the new model over the traditional straight-line approach of biotech. The rewards could be great in the traditional model, but with the odds weighing in only around 5% at best that any pre-clinical biotech asset would make it to launch, the risks are equally high. The acquisition of Varian by Healthtech plays to the strengths of the new portfolio model not only in drug pipeline but also by bringing in experts in an area that could attract additional investment. Again, that’s an appetizing part of the basket model. “The fact that [Varian Bio is] developing therapies to target difficult-to-treat cancers such as pancreatic cancer demonstrates just how innovative their team is,” said Healthtech Solutions Chairman and CEO David Rubin in a statement disclosing the acquisition. “Precision oncology is an exciting field and we’re thrilled to be a part of it,” he added. For more information, visit the company’s website at www.MyMediScan.com. NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://ibn.fm/HLTT

• SRAX held first-ever virtual Sequire Cannabis Conference on April 20, 2021
• Event featured over 40 cannabis company presentations, keynote appearances by Steve DeAngelo, Dr. Sue Sisley, Emily Paxhia, Steven Hawkins, Dr. Jeffrey Chen
• Sequire provides data analytics tools that help public companies track investor activity, such as investor tracking, warrant management, shareholder surveys
• Sequire has grown to over 3 million users across 183 companies since 2019

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, recently held its first-ever virtual Sequire Cannabis Conference on April 20, 2021 (https://ibn.fm/nr7Pd). Nearly one million active small-cap investors were invited to the event, which featured presentations by over 40 cannabis companies along with keynote appearances by prominent industry experts such as Steve DeAngelo, Dr. Sue Sisley, Emily Paxhia, Steven Hawkins, and Dr. Jeffrey Chen. The cannabis industry has undergone seismic shifts in the last decade that included the publication of notable scientific studies and extensive research reviews (https://ibn.fm/GbwCt), along with legalization in several states (https://ibn.fm/dT9BO). The industry has since exploded with thousands of new companies in various sectors, including plant genetics cultivation, product development, e-commerce portals and physical dispensaries across the United States. Presenting at the Cannabis Conference were prominent industry leaders such as Steve DeAngelo, a lifelong activist, entrepreneur and co-founder of Harborside, The Arcview Group, The Last Prisoner Project non-profit organization, and the Radio Free Cannabis podcast. He was interviewed by Emily Paxhia, an investment expert who has reviewed thousands of companies in the cannabis space in addition to working with numerous founders in various capacities. Also featured at the conference were interviews with Dr. Sue Sisley and Steve Hawkinsby Dr. Jeff Chen, co-founder and CEO of Radicle Science, and Founder and Director of the UCLA Cannabis Research Initiative. Sisley is an Arizona-based physician, President of Scottsdale Research, and Principal Investigator for FDA-approved randomized controlled trials. Hawkins is the President & CEO of the United States Cannabis Council and Executive Director of the Marijuana Policy Project. The Cannabis Conference is one of many industry-specific events SRAX plans to host on Sequire this year. Besides event management, the platform empowers public companies with data analytics tools that include investor tracking, warrant management, and shareholder surveys. Since its 2019 inception, the platform has grown to include over 3 million users across 183 public companies and is rapidly becoming the premier analytics platform in the investment space (https://ibn.fm/jBwJf). SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. Replays of SRAX’s Sequire Cannabis Conference can be accessed at https://cannabis-conference.mysequire.com/. For more information, visit the company’s websites at www.SRAX.com and www.MySequire.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Beijing-based Infobird has built rich experience in the customer engagement industry that covers SaaS solutions such as cloud call center, intelligent telemarketing, AI Chatbots, and has now closed its IPO on the NASDAQ exchange.
• Infobird’s artificial intelligence (“AI”) solutions help clients to minimize costs and maximize potential revenues.
• The company’s self-developed cloud-native architecture and patented AI technologies work with a no-code development platform to help companies focus their efforts and financial outlays where they are most needed.

B2B artificial intelligence (“AI”) solutions company Infobird (NASDAQ: IFBD) is building next-level operations in tandem with the Beijing, China-based company’s April 20 IPO debut on The Nasdaq Capital Market (https://ibn.fm/TPyf7). Infobird has built a reputation as a premier provider of customer engagement SaaS solutions in China that use automated and smart solutions to maximize value for its clients through reduced corporate costs that don’t impinge on the clients’ ability to generate and increase revenues. The company’s self-developed cloud cloud-native architecture and patented AI technologies, for example, work with a no-code development platform that allows enterprise-building companies to focus on managing their operations as they know best, while relying on the technological expertise of application builders for only the most necessary development efforts, likewise enabling the automation of AI-empowered call center features to handle many of the routine and repetitive functions that human personnel might otherwise be needed for in large numbers. Infobird is one of the first enterprises to apply intelligent technology to customer service industry. Over the past decade, the company has built a client base of over 10,000 paid user accounts from 358 customers in finance, education, public services, consumer products and health care. While its primary focus is on key corporations in the finance industry, it has served clients from other industries as well, such as e-commerce giant Alibaba (NYSE: BABA). As one of the leading software-as-a-service (SaaS) providers in China, Infobird uses a highly successful business model in which centrally hosted software is licensed to customers via a subscription plan that not only generates recurring revenue but also opens wide channels of ancillary revenue streams. The SaaS sector has experienced significant growth in recent years and China is now the second-largest market in the world for cloud infrastructure spending. During the past 20 years, Infobird has continually expanded its technological boundaries, acknowledging that the “intelligence” of intelligent customer service cannot be realized by a single technology and must instead depend on the interaction and integration of various technological systems. With the explosion of big data, AI and other technologies, Infobird has continuously integrated voice recognition, intelligent interaction and other technologies into its product research and development. By integrating big data, AI, cloud computing, 5G and other technologies, the company can provide smart and value-added solutions for all customer engagement processes and thus empower the enterprises to better interact with their customers, to reduce costs for the operation and ultimately to increase sales revenue. For more information, visit the company’s website at www.Infobird.com/en/index.html NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD

• Tryp Therapeutics is a pharmaceutical company with a focus on developing clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways
• The company currently has two drug candidates in development: TRP-8802 (targeting fibromyalgia, eating disorders and chronic pain conditions); and TRP-1001 (targeting soft tissue sarcomas)
• Through its PFN(TM) program, the company is focused on developing psilocybin-based drug therapies for certain neuropsychiatric disorders that offer increased efficacy and reduced risk of abuse or addiction
• The company’s management team has decades of experience in the life sciences industry, including the pharmaceutical and biotechnology markets
• Oncology therapeutics are expected to account for roughly 30% of all drug sales by 2024, representing a total market valued at approximately $200 billion

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on developing clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways.

The company was founded in 2019 and is headquartered in San Diego, California.

Innovative Drug Pipeline

Tryp’s current focus is on advancing its two drug development platforms: its Psilocybin-for-Neuropsychiatric Disorders (PFN(TM)) program targeting fibromyalgia, eating disorders and chronic pain conditions; and razoxane for soft tissue sarcomas. The company intends to explore opportunities to monetize these platforms after generating Phase 2b clinical data.

The company’s development plans cover three strategic initiatives:

• Develop: Tryp intends to utilize the FDA’s 505(b)(2) regulatory pathway with available third-party preclinical data to shorten the timelines and lower the cost of its development programs.
• Protect: Tryp plans to utilize regulatory exclusivity, patents, trade secrets and proprietary know-how to protect the commercial lifespan of its drug candidates.
• Monetize: Tryp intends to seek out licensing, acquisition and co-development opportunities for drug candidates following their Phase 2 stages of development.

PFN(TM) Program

Through its PFN(TM) program, the company is focused on developing psilocybin-based drug therapies for certain neuropsychiatric disorders that have distinct advantages over other drugs currently on the market or in development. These advantages include:

• Increased efficacy
• Natural blood-brain barrier penetration
• Enhanced safety and toxicity profiles
• Reduced risk of abuse
• Reduced risk of addiction

Tryp’s PFN(TM) program features its lead drug candidate, TRP-8802. The company’s initial indication for TRP-8802 is fibromyalgia.

Fibromyalgia is believed to be a neurosensory disorder characterized in part by abnormalities in pain processing by the central nervous system. The three drugs with FDA approval for the treatment of fibromyalgia are Pregabalin (Lyrica(R)), Duloxetine (Cymbalta(R)) and Milnacipran (Savella(R)), which are only effective for a portion of patients suffering from the condition.

Tryp plans to seek FDA approval to proceed directly to Phase 2 clinical trials evaluating TRP-8802 as a treatment for fibromyalgia based on existing preclinical and clinical data for the active pharmaceutical ingredients in TRP-8802.

Tryp’s pipeline of indications for TRP-8802 also includes eating disorders and certain forms of chronic pain. The company expects to initiate Phase 2a clinical trials in these areas in 2021.

Tryp recently partnered with Albany Molecular Research Inc. (“AMRI”) for the manufacture of the company’s synthetic psilocybin using proprietary methods. AMRI has initiated the process of manufacturing a 200g non-GMP demonstration batch of psilocybin and will produce a batch of GMP psilocybin in mid-2021. As the holder of the Drug Master File, Tryp expects to be the only U.S.-based manufacturer of synthetic psilocybin in the industry.

Razoxane

Tryp’s second drug candidate, TRP-1001 (razoxane), is being developed as a treatment for soft tissue sarcomas and has been evaluated in multiple Phase 2 clinical trials conducted by clinicians unaffiliated with Tryp. The company believes that existing clinical data regarding razoxane will likely allow TRP-1001 to be studied in a Phase 2 trial without the need for extensive preclinical or Phase 1 trials.

Sarcomas are rare tumors that are derived from connective tissues in the body and comprise 7% of all cancers in children. In 2018, an estimated 13,000 new cases of soft tissue sarcoma were diagnosed, with the tumors resulting in over 5,000 deaths during that year in the United States alone (https://ibn.fm/nWOGq).

Market Outlook

With its drug development programs targeting multiple indications, Tryp is well positioned to capitalize on growth opportunities spanning a range of therapeutic markets. The global oncology drugs market, in particular, represents a sizable opportunity.

In 2018, oncology indications accounted for 25% of all drug sales, representing approximately $151 billion in market revenues. By 2024, spending on oncology-targeted therapeutics is expected to top $200 billion and account for roughly 30% of total drug sales, according to a study by Cowen Equity Research (https://ibn.fm/9iZhM).

Valued at $764 million in 2020, the global fibromyalgia treatment market presents unique opportunities for development due to the limited number of approved therapies. With treatment trending upward, the market is expected to grow at a CAGR of 9.2% and reach $1.4 billion in value by 2027 (https://ibn.fm/G66e7).

Management Team

Greg McKee is the Chairman and CEO of Tryp Therapeutics. He has more than 20 years of life sciences management and venture investment experience that he brings to the company. Before taking his role at Tryp, he was the founder of Torrent Ventures, an early-stage digital health and medical technology venture fund. Mr. McKee also served as the CEO of CONNECT, the largest Southern California start-up accelerator. Before this, he was the chairman, president and CEO of then publicly traded Nventa Biopharmaceuticals, which successfully merged with Akela Pharma. Mr. McKee earned a B.A. in Economics from the University of Washington, an M.A. in International Studies from The Joseph H. Lauder Institute, and an MBA from the Wharton School at the University of Pennsylvania. He has been a member of the Young President’s Organization (“YPO”) since 2006.

James Gilligan, Ph.D., is the company’s President and Chief Science Officer. He has over 35 years of experience in the life sciences industry, including research and development, clinical development, international regulatory affairs and manufacturing. Before joining Tryp, Dr. Gilligan was the Co-Founder and Managing Partner of The Bracken Group, a life sciences consulting firm. He was also the Co-Founder of Unigene Laboratories, which develops technology for the recombinant manufacture of peptide hormones. Dr. Gilligan received his Ph.D. in Pharmacology from the University of Connecticut and a MSIB from Seton Hall University. He continued his post-graduate education at the Roche Institute of Molecular Biology.

Tom D’Orazio is the Chief Operating Officer of Tryp Therapeutics. He has extensive experience in leading the development and commercialization of vaccines, drugs, radiopharmaceuticals and biologics. His prior leadership experience has been in commercial planning, marketing, partnership and business development roles. He was formerly the CEO of ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), where he led the transition from a private company to a public one. He co-founded and served as CEO of Superna Life Sciences, a specialty-pharma company focusing on niche drugs for cancer patients in Canada. Mr. D’Orazio has an MBA from Vanderbilt University with a primary focus in both finance and marketing and a B.Sc. in chemistry from Loyola University of Chicago.

Luke Hayes is the company’s Chief Financial Officer. He has played an active role in the life science industry for over 20 years with technology transfer, venture capital and finance experience. His career started with business development for Dow Chemical (NYSE: DOW), with responsibility for pharmaceutical customers such as Eli Lilly and AbbVie. Mr. Hayes has spent more than a decade doing venture capital investing while supporting companies as a director and advisor. He earned a B.S. in Chemical Engineering from Brigham Young University and an MBA from the UCLA Anderson School of Management.

For more information, visit the company’s website at www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• Routine virus testing is effective overall employer strategy for providing employee safety and business continuity
• More research needs to be done on how long vaccines are effective, if booster shots will be needed
• Only 26% of the U.S. is fully vaccinated; vaccinated individuals can still spread the virus

United Medical Equipment Business Solutions Network provides solutions that fit the ever-changing needs of the nation’s workforce during the COVID-19 pandemic through the distribution of rapid antigen tests and COVID-19 rapid kit testing. As employers begin to reopen worksites, routine virus testing is an effective overall strategy for providing employee safety and business continuity.

Chief medical advisor to the president Anthony Fauci, MD, has stated that booster shots for COVID-19 may be needed (https://ibn.fm/NWcBr). The vaccines currently being offered are said to provide protection for at least six months, but more research needs to be done on how long they are effective. The appearance of COVID mutations may also lead to the need for boosters. Right now vaccination efficacy is simply a moving target because the vaccines have not been around long enough to know how long they will be effective fully.

To achieve herd immunity, Fauci has said that the country needs to have 70% to 85% of the country immune either through vaccinations or previous infection. As of April 21, 2020, around 26% of the population was fully vaccinated (https://ibn.fm/w57PZ).

The experts agree that it will take time to suppress the spread entirely. The fact that those who are vaccinated are still capable of spreading the virus to others makes the process even slower; the task becomes even more daunting as fewer Americans practice public health safety measures.

COVID-19 rapid kit testing is needed now more than ever. The pandemic isn’t over, despite the urgency to go back to life as usual. United Medical is making it possible for businesses and health-care facilities to maintain safety and health among workers and clients.

United Medical is a trusted supplier of personal protective equipment (“PPE”) as well as FDA-approved COVID-19 rapid antibody test kits and FDA – EUA authorized rapid antigen tests. The company works with its customers’ specific testing needs and goals to build a customized and flexible employee testing solution that works for the employer, the employees and the customer’s budget.

United Medical is committed to addressing the needs of America’s aging population throughout the global pandemic and far into the future. By offering COVID-19 rapid kit testing, the company is doing its part and continually evolving its efforts to protect the community from COVID-19.

For more information, visit the company’s website at www.UnitedMedSolutions.com.

NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed

 

• Speaking in an interview with Oren Klaff, Nextech President Paul Duffy noted that AR technology, as a concept, was growing as more people understand its use
• He foresees significant milestones and breakthroughs, as well as an extensive global adoption of AR technology
• His prediction is in line with a recent industry report that shows that the AR market will grow at a CAGR of 43.8% from 2021 to 2028

According to a report by Grand View Research, the global augmented reality (“AR”) market is estimated to grow at a 43.8% CAGR from 2021 to 2028, reaching $340.2 billion up from a market size value of $26.75 billion. The report attributes this growth to new innovations in the AR space that have led to the adoption of this technology in multiple industries. Presently, more people are using AR-based tools and platforms to shop, interact with their peers on social media and learn, in turn, fueling growth (https://ibn.fm/u7wMy). The report tells of a world that a 2017 Harvard Business Review (“HBR”) article predicted (https://ibn.fm/24iNX). The authors forecasted that AR, which was in its infancy at that time, would enter the mainstream and transform different industries and organizations, including learning institutions and social enterprises. In an interview with bestselling author Oren Klaff on his “The Dealmaker Show” podcast (https://ibn.fm/OzLs9), Paul Duffy, President of Toronto-based Nextech AR Solutions (CSE: NTAR) (OTCQB: NEXCF), gave a positive outlook for the AR market and industry, indirectly seconding the predictions. “The whole concept of augmented reality is just galloping in growth right now, not just in financial terms, but in mindshare, in people understanding its use. I personally believe that, over the next decade, augmented reality itself will become a new form of mass medium that we will all use to communicate at one level,” Duffy stated. Duffy predicts that the next decade will witness significant AR technology milestones and breakthroughs that will lower the cost and size/weight of eyewear but still offer expanded functions and features, including support for multiple ways of controlling the devices. Moreover, he noted that breakthroughs leading to revolutionary experiences would hit the market in three to five years, effectively playing a role in making AR technology bigger and “omnipresent.” “I’m seeing, at a global level, a large adoption of the technology. What I mean by this is there are more and more folks who are seeing its as a technology that they can apply, and they can use to gain value intrinsically in what they’re already doing,” Duffy continued. Asked about businesses that should adopt AR, Duffy highlighted three key areas: e-commerce companies, hybrid and virtual events, and brands whose operations encompass advertising. He credited Nextech’s growth to its strong leadership team and the fact that it offers AR solutions for each of these three areas. In April 2021, Nextech launched the LiveX Digital Experience Platform (“DXP”), its hybrid and virtual events platform, which it will use to stream an upcoming two-day event, leveraging its AR technological solutions to provide an engaging experience for attendees (https://ibn.fm/DzNuw). Similarly, the company launched an AR-capable Ad Network early this year. Nextech also offers AR-based e-commerce solutions, effectively taking part in the online commerce megatrend. Thanks to its broad approach to offering innovative AR solutions, the company has witnessed tremendous growth year over year. In its recently released full-year report, for example, Nextech reported a 342% increase in revenue and a 320% growth in gross profits. Based on Paul Duffy’s positive outlook for the AR industry, Nextech looks poised to continue this growth through the coming years. For more information, visit the company’s website at www.NextechAR.com. NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at https://ibn.fm/NEXCF

• Rare-earth metals market expected to almost double by 2026, driven by consumer and industrial electronics demand
• REEs are considered critical minerals by the government, but China absorbs biggest share of world supply
• Energy Fuels remains top U.S. uranium producer, determined to expand into rare earths and bring back production to US

As a leading U.S. uranium producer that recently expanded into the promising rare earths market, Energy Fuels (NYSE American: UUUU) (TSX: EFR) may hold the key to restoring sustainable, low-cost, domestic rare earth element (“REEs”) production in the United States (https://ibn.fm/3JIBW). That position could prove to be profitable, as the rare earth metals market is projected to grow at a CAGR of 12.3%, expanding from $5.3 billion in 2021 to $9.6 billion by 2026 (https://ibn.fm/OvsW0).

A number of critical industries, such as green technology and defense, consume rare earth elements. These elements are used in permanent magnets, metal alloys, phosphors, catalysts, polishing and glass additives. Rare-earth permanent magnets are expected to be the main growth drivers, with projected growth rates of 12% to 14% in the next decade. Such elements are used around the world in major consumer and industrial electronic applications including electric vehicles, wind energy, smartphones and hard disk drives, but China absorbs the biggest share of current world supply (https://ibn.fm/EUwVj).

Energy Fuels appears poised to become a key player in the rapidly expanding REEs market and revive production of the elements in the United States. Already the largest uranium producer in the country, with more production capacity and assets than any other U.S. uranium company, UUUU developed a complementary rare earth business in 2020. The strategic move was possible because one of the most valuable rare earth bearing minerals (monazite) also contains uranium that must be recovered before further downstream REE processing and refining can occur.

Energy Fuels is the key U.S. player for the raw materials, such as uranium, rare earths and vanadium, that make many clean energy and advanced technologies possible. These materials are categorized as critical minerals by the U.S. government, and both Congress and the Biden Administration support restoring U.S. production capabilities in these key industries. U.S. companies such as Energy Fuels produce critical minerals to the highest global standards for the protection of human health and the environment

UUUU believes that it might hold the key to restoring a sustainable, low-cost, domestic rare earth production in the country. “I’m not exaggerating when I say that rare earths at Energy Fuels’ White Mesa Mill in Utah might be the best resource opportunity I’ve encountered in my 45-year mining career,” said Energy Fuels president and CEO Mark S. Chalmers following the arrival of the first shipment of natural monazite ore at the company’s White Mesa Mill. This marks a significant milestone as monazite is one of the best naturally occurring rare earth minerals, but it is mainly sold to China’s rare earth and nuclear industries.

With a revived interest in the uranium sector and the company’s rapid progress in the REE space, combined with rising vanadium prices, Energy Fuels appears poised to seize further growth opportunities for the company and its shareholders.

For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

• Treeletrik, Ideanomics’ subsidiary, inked a $274 million three-year deal with two distributors to supply 200,000 e-motorbike units to Indonesia
• The deal will result in Treeletrik’s expansion, enabling Ideanomics to continue providing its shareholders with high-growth opportunities
• Indonesia, the third-largest motorcycle market in the world, is a promising market for e-motorbikes, as evidenced by the projected growth at a CAGR of ~21% from 2019 to 2025

The Indonesian electric motorbike market is expected to grow at a CAGR of 20.96% from 2019 to 2025, reaching $816.2 million from $364.4 million (https://ibn.fm/SBUHm) amid clamor around the high vehicular pollution and the need to reduce CO2 levels in the country. Suggestions point to the introduction of a sustainable mode of transport as the solution to these problems. Further, the Association of Southeast Asian Nations (“ASEAN”) region, of which Indonesia is part, is committed to reducing final energy consumption in the road transport sector by 2040.

As a manufacturer of 100% electric vehicle (“EV”) products, including motorbikes, this is welcome news for Malaysia-based Tree Technologies Sdn Bhd (“Treeletrik”), a portfolio company of Ideanomics Inc. (NASDAQ: IDEX). Recently, Treeletrik announced it had inked a $274 million three-year deal with two Indonesian distributors, PT Pasifik Sakti Enjiniring and the Nahdatul Ulama Board (“PBNU”), that will see it supply 200,000 units of its electric motorbikes to Indonesia in yearly tranches. In 2021, Treeletrik will deliver a minimum of 10,000 units, followed by up to 90,000 units in 2022 and, finally, up to 100,000 units in 2023 (https://ibn.fm/hV3ao).

The partnership places Treeletrik in a favorable position to leverage Indonesians’ love for two-wheelers and generate revenue as a result. In 2019, for example, approximately 6.49 million motorbikes were shipped into the country, effectively making Indonesia the third-largest motorbike market in the world, behind India and China. Indonesia claimed this third position thanks to the increasing demand for cheaper personal transport, high disposable income, upgraded road infrastructure and rising popularity of loan and credit facilities (https://ibn.fm/FISWm).

While Treeletrik is bound to benefit from a combination of these factors, which will naturally increase the sales of its motorbikes, the evident demand for cheaper personal transport alternatives is likely to stand out as a key driver. Its electric motorcycles offer a more affordable means of transport than motorbikes with combustion engines.

The e-motorbikes, which have a daily estimated range of between 80 and 120 kilometers and can cruise at an average speed of 65-90 km/hour, run at an estimated cost per kilometer of between RM0.01 and RM0.02 ($0.0024 to $0.0049), when an electricity rate of RM0.571/kWh ($0.14), the highest tariff by the Tenaga Nasional, is used.

In contrast, an independent comparison conducted in 2017 pitting nine gasoline-powered motorcycles against one of Treeletrik’s motorbike models, the T-70, established that the gasoline-powered bikes were more expensive to run per kilometer at RM3.7-12 ($0.90-2.92) compared to the T-70’s RM0.0072 (https://ibn.fm/hMDCW), a figure consistent with the current RM0.01-0.02 estimate.

The affordability aspect of the e-bikes formed part of a statement by Treeletrik CEO Datuk Viswananthan Menon, who hailed the company as a forerunner in taking fully electric bikes to the ASEAN region and beyond, pioneering a new way of mobility. “Our 100% electric motorbikes offer customers long-term cost savings and more importantly contribute towards an overall positive impact to the environment,” he said.

According to Menon, the deal Treeletrik entered with the distributors, other similar sizeable orders and ongoing discussions with other countries interested in its range of e-bikes will result in its significant expansion in both its home country and in international markets. Thus, Ideanomics, which acquired a controlling stake in Treeletrik in 2019 as part of its strategy to drive the adoption of commercial EVs, is well placed to continue providing shareholders with high-growth opportunities.

For more information, visit the company’s website at www.Ideanomics.com.

NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at https://ibn.fm/IDEX

• RYAH recognizes the value data combined with analytics can bring to almost every industry.
• Company focused on becoming a technological leader in the plant-based treatment market.
• RYAH’s easy-to-operate line of products help foster a seamless dose-control experience that generates insightful data.

A recent Forbes article called it the “oil” of the fourth industrial revolution (https://ibn.fm/x7inY) while a Gartner article noted it was a core function for businesses focused on success in 2021 (https://ibn.fm/wQ1Ht). Whatever it is called, data has become a hot commodity in today’s world, and the RYAH Group is dedicated to transforming patient care through big data and AI to unearth breakthrough discoveries that will reshape understanding of plant-based medicines.

“Self-driving cars, lifelike robots, and autonomous delivery drones are the sexy, headline-grabbing face of the digital transformation that we see all around us today,” stated the “Forbes” article. “None of these would be possible, though, without data – the oil of the fourth industrial revolution – and the analytic technology we’ve built to allow us to interpret and understand it.”

The Gartner article noted that “business leaders are beginning to understand the importance of using data and analytics to accelerate digital business initiatives. Instead of being a secondary focus — completed by a separate team — data and analytics is shifting to a core function. However, business leaders often underestimate the complexities of data and end up missing opportunities.”

RYAH recognizes the value data combined with analytics can bring to almost every industry, and it has focused on becoming a technological leader in the plant-based treatment market. The company has created unique products that pair a growing ecosystem of therapeutic plants with top-rated apps, devices, and services.

RYAH’s easy-to-operate line of products help foster a seamless dose-control experience that generates insightful data, making it simple for doctors, researchers, and end users to hone in on the ideal settings for the best possible treatment outcomes with RYAH Smart Patch, RYAH Smart Inhaler, RYAH Smart Pen, and upcoming RYAH MD platform.

These proprietary IoT devices and data analytics are supported by patented AI technology to aggregate and correlate HIPAA-compliant dosing data from seed to consumption. RYAH is then able to conduct predictive analyses to help doctors, researchers and end users create personalized dosing regimens that can accurately foresee patient outcomes.

RYAH’s unique approach has allowed it to carve a promising niche in the $100.3 billion medical plant market, with exciting potential in both the IoT and data intelligence industries.

For more information, visit the company’s website at www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

BAND Royalty, an enterprising music technology company, is launching a series of 3,000 NFTs that provide fans a unique NFT collectible, that will eventually be able to give owners access to share in the various music royalty revenues produced by some of the most popular songs, performed by some of most successful musicians around the globe.

1. BAND Royalty’s new digital economy focusing on music is part of its preparations to launch an NFT/crypto ecosystem that unlocks as much of a musician’s music royalties as possible by having them team up with their fans. This includes BAND Royalty publishing as well as its upcoming music label, BAND Music Chain Records
2. BAND’s NFTs are designed to grant access to the revenues of BAND’s in house Performance Rights music royalty pool, that includes songs performed by artists such as Beyonce, Jay-Z, Justin Timberlake, Cher and Rihanna. BAND will go on to share full access to a further two additional royalty rights pools, Publishing Rights and Synch Royalties, totally three royalty pools. Just like basketball fans have NBA Topshots, BAND NFTs are doing the same thing for music fans, creating a series of collectible NFTs that give them access to share in the royalties of their most beloved songs and artists.
3. The NFT market is finding it’s place in the larger digital economy — tripling in valuation during 2020 and continuing on to record sales in 2021, over $500 million, including Christie’s highest ever recorded art auction for a living artist at $69 million, coming from Beeple’s digital art sale in March.

Ten years after Bitcoin creator Satoshi Nakamoto sent his final emails to fellow developers, the cryptocurrency’s roller coaster ride on the market continues to reach new heights (https://ibn.fm/6Gaqo) even as a large swath of the world’s population continues to be mystified by what cryptocurrencies entail — including the majority of those who invest in the digital asset (https://ibn.fm/Uh7lp). Now in 2021 we are bringing on a whole new range of other digital properties to be stored on the blockchain, being spearheaded by non-fungible tokens (“NFTs”) rapid rise as the fastest growing asset class of 2021 last year, after it tripped in value tripled in only a few months, indicating a significant store of value exists there (https://ibn.fm/kehtd). Time magazine reported NFTs garnered another $200 million between February and March alone this year, with work by digital artist Mike Winkelmann (known as Beeple) selling for a record $69 million at Christie’s on March 11 (https://ibn.fm/1GJ31). NFTs continue to accelerate a larger trend of the digital economy innovation, as the public continues its increasing fascination with the a crypto-economy. NFTs seem to be particularly suited to artists, allowing them to profit from unique, trade-able representations of their work that are in a sense owned digitally but not copyrighted, not unlike a mass-produced baseball card or poster with genuine autographs adorning its face that can be bought and sold for whatever value someone attaches to it. Entertainment technology-driven firm BAND Royalty is creating its own pioneering space in this rapidly monetizing new NFT market, creating its first limited edition of 3,000 music NFTs that will allow fans of both the crypto and music industries to not only collect one of the 3,000 NFTs, but to also eventually “stake” it within one of their three “royalty pool” that give them the opportunity to share in the royalties from various artists and songs they love within the BAND music royalty catalog. The royalties are derived from either published versions of the music, or public and mechanical performances of the music, or synchronization with some kind of visual media such as film, advertisements or video games. The revenue generated from the BAND music royalty catalog is not guaranteed, just as market investment revenues can’t be guaranteed. Monetization potential for a BAND NFT holder who decides to stake has many variables, that depend upon the number other stakers there in that specific BAND Royalty music pool, the number of NFTs each holder stakes, the amount of royalty generated that quarter on how many times the songs were played, the length of time that the staker stakes, and how accurately they fulfill all of the requirements that makes them eligible to be a staker. Stakes in the three BAND music royalty pools can be placed for a period ranging from 90 days to five years once BAND’s Music Royalty Pools smart contracts open up at the start of Q3 in July 2021.  All those holders of BAND NFTs during Q2 will automatically qualify for royalty payments for Q2, provided they stake immediately upon the opening of the royalty pool smart contract. BAND Royalty debuted it’s NFT launch by sharing a partial glimpse into its current performance royalty catalog of over 50 songs performed by various artists including Beyonce, Jay-Z, Justin Timberlake, Cher, will.i.am, Timbaland and Rihanna. BAND Royalty intends to sell two more series of limited edition BAND NFTs with new artwork continuing to celebrate diversity and inclusion, by August and a final fourth NFT series after that, including tokens and an app launch. Each BANF NFT series will include 3,000 NFTs, completing the entire series at a total of 12,000 BAND NFTs. Similar to both Hashmasks and CryptoPunks limited edition series, the BAND NFTs are designed to be stand-alone collector items that provide collectable value, even without requiring access to royalties component, which bring a unique benefit not seen in any other NFT release to date. “The performance royalty rights of the music that BAND has shared from their website, validates that for the next 8 years BAND Royalties operating Singaporean company owns the songwriter’s ‘writer rights’ to this entire collection. This is very important because it opens the BAND catalog to royalties whenever the song is played or performed, even if it is not performed by the specific artist who made the song famous,” the company states in a news release explaining how its NFT product works, citing the enormous revenues (over $10m) that Whitney Houston’s performance of “I Will Always Love You” generated for original artist Dolly Parton (https://ibn.fm/VHAmM). “In 20 years, when every corporation uses blockchain to track its supply lines, every bank uses smart contracts to manage its money flows, and Justin Beiber is using NFTs to divide up and monetize his entire discography directly with his fans; we will look back on small moments like these and remember where it all started…,” the BAND news release states. For more information, visit the company’s website at www.BANDRoyalty.com. NOTE TO INVESTORS: The latest news and updates relating to BAND Royalty are available in the company’s newsroom at https://ibn.fm/BAND